Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2830141 | 0.78 | TDP1 (0.41) | TDP1POLBMEN1KMT2ACYP2C9 | |
| SCHEMBL7054295 | 0.78 | TDP1 (0.41) | TDP1LMNATP53POLBL3MBTL1 | |
| SCHEMBL5174989 | 0.72 | TDP1 (0.46) | TDP1POLBMEN1KMT2ACYP2C9 | |
| SCHEMBL7054292 | 0.72 | AR (0.45) | TDP1TP53POLBMEN1KMT2A | |
| SCHEMBL5498036 | 0.72 | KDM4E (0.47) | TDP1LMNATP53POLBL3MBTL1 | |
| SCHEMBL25122834 | 0.70 | MCL1 (0.35) | — | |
| SCHEMBL20515068 | 0.69 | TDP1 (0.44) | TDP1POLBMEN1KMT2ACYP2C9 | |
| SCHEMBL13766359 | 0.69 | MEN1 (0.48) | POLBL3MBTL1MEN1KMT2AALDH1A1 | |
| SCHEMBL2783116 | 0.69 | CYP2C9 (0.54) | TDP1TP53POLBL3MBTL1MEN1 | |
| SCHEMBL3674837 | 0.69 | TDP1 (0.46) | TDP1POLBMEN1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2488486-B1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARM INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-9622991-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9144557-B2 | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARMACEUTICALS INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-09-10 | — | — | US | disclosed |
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-08-28 | — | — | US | disclosed |
| EP-2642994-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | Ligand Pharmaceuticals Incorporated (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2488486-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | Ligand Pharmaceuticals Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2012068406-A2 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2011046954-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | LIGAND PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243324-A1 | USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS | HGF, EPOR, MPL | TDP1 4799/4885LMNA 4611/4885TP53 828/4885 |
| US-20150252043-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | TDP1 4089/4885LMNA 3995/4885TP53 309/4885 |
| US-20120295904-A1 | HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES | MPL, CSF3R, HGF | TDP1 4089/4885LMNA 3995/4885TP53 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.